Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.
You may also be interested in...
Gilead Complera Launch Imminent Following FDA Approval
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
Gilead Complera Launch Imminent Following FDA Approval
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.